Pfizer rheumatoid arthritis drug effective in study | Industries | Healthcare | Reuters

RAREUTERに抗RAが3題。PfizerのCP690, RocheのaIL6R, J&JのaTNFa(ゴリムマブ)。学会が近い？

CP-690,550
Pfizer rheumatoid arthritis drug effective in study Industries Healthcare ReutersSignificantly more patients reached the ACR 20 goal on the medicine than did those who received a placebo.

tocilizumab
Roche arthritis drug effective in late-stage trial
メトトレキセートとの併用で統計的優位に効果あり。
In the study involving nearly 1,200 patients, those who received Actemra by infusion every four weeks plus an older medicine, methotrexate, experienced significantly lower progression of joint erosion and joint space narrowing than those who received methotrexate and a placebo.
Both the 8 milligram/kilogram and 4 mg/kg doses achieved statistical significance compared to the placebo group, according to data to be presented at the American College of Rheumatology meeting in San Francisco next week.
Actemra, known chemically as tocilizumab, is an anti-interleukin-6 receptor antibody and works in a different way than the existing class of biotechnology medicines that block an inflammatory protein called tumor necrosis factor (TNF), such as Roche and Genentech Inc's (DNA.N: Quote, Profile, Research, Stock Buzz) Rituxan.

golimumab(sc, 4週に1度)
J&J arthritis drug effective after 1 year-study
The drug, a next-generation anti-TNF therapy, is administered every four weeks by subcutaneous injection. Anti-TNF drugs are a class of biotechnology medicines, including J&J's Remicade, that are used to treat inflammatory diseases.
Through one year, 78 percent of patients who continued in the golimumab 50 mg group and 74 percent of patients on the 100 mg dose achieved the ACR 20 goal, researchers said. Some attained ACR 50 and ACR 70 responses, they said.